Targanta Therapeutics

Company: Targanta Therapeutics
Financing: $70 million third round
Website: http://www.targanta.com/

Cambridge, MA-based Targanta Therapeutics landed a huge $70 million third round back in February. The round was The financing was led by Brookside Capital, Skyline Ventures, Radius Ventures, and OrbiMed Advisors, and included existing investors Seaflower Ventures, VenGrowth Advanced Life Sciences Fund, and the Canadian Medical Discoveries Fund, among others. 

Targanta’ lead drug candidate is oritavancin for complicated skin and skin structure infections; it’s also in Phase II trials for catheter-related bacteremia and nosocomial pneumonia. The drug developer said that the money would be used to file an NDA for oritavancin, which is anticipated in early 2008. In May Targanta filed an $86 million IPO designed to help it quickly commercialize Oritavancin, which will have a shorter period of marketing exclusivity due to delays earlier in its development.

Related Articles:
Targanta raises $70M in third venture round. Report
Targanta files for $86M IPO to push antibiotics. Report

Targanta Therapeutics
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.